Status: Recruiting
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Participants needed: 73
Trial details
Phase: Phase 2Age: 19-65Biological sex: AllType: InterventionalSponsor: NEXTGEN BioscienceUpdated: Apr 13, 2026Locations: 2
Eligibility criteria
Men or women between ≥19 and ≤65 years of age at the time of informed consent [+4]
ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring... [+2]